抗瘤酮A_(10)的致突变性研究  

A STUDY OF MUTAGENICITY ON ANTINEOPLASTON A10

作　　者：于人江 谢根法 周玲 崔淑香 

机构地区：[1]山东省医科院药物研究所细胞室,济南250001

出　　处：《癌变．畸变．突变》1992年第3期18-20,14,共4页Carcinogenesis,Teratogenesis & Mutagenesis

摘　　要：以Ames试验、人外周血淋巴细胞染色体畸变试验及小鼠骨髓嗜多染红细胞(PCE)微核试验测试了抗瘤酮A_(10)的致突变性能。有/无S9混合液的条件下,实验组的回变菌落数与阴性对照组基本相似;并无明显的剂量效应关系,0.4,2,10mg/ml的A_(10)均未引起人外周血淋巴细胞染色体畸变率的增加;小鼠口服A_(10)6000、3000、1500mg/kg,微核率分别为3.8、2.4、1.8％,与阴性对照组(1.7‰)相比无明显差异。在这些测试系统中,未见到抗瘤酮A_(10)有致突变作用。The mutaganic effects of antineoplaston A10 Were studied with using Ames test, the test of micronucleus of polychromatis erythrocytes in bone marrow of mouse and the analysis of chromosome aberration of peripheral blood lymphocytes from adult healthy individual. The results showed that there were not significant defferences between the induced back mutation colony numbers of the test group (TA97, TA98, TA100102) and the control group with or without S9 mix. No linear relationship on doses and effects was found. 3 doses of antineoplaston A10 (0.4, 2, lOmg/ml) did not increase the rate of the chromosomal aberration of peripheral blood lymphocytes from adult healthy individual. When mouse treated with the doses of 6000, 3000 and 1500mg/kg on oral formulation of antineoplaston A10, the micronucleus rate were 3.8, 2.4 and 1.8‰, and the control group was 1.7‰. There was not significant difference in two groups.Therefore,antineoplaston A10 did not result in genetic damage in our experiment.

关 键 词：抗瘤酮A10 致突变 

分 类 号：R979.19[医药卫生—药品]